BCAB

Conviction 67HealthcareScan · Thu, Jun 25, 2026

BCAB$3.54-6.60%

ResistanceSupportVol 14

Vol MA14 67.19K

Mar 26Apr 14May 1May 19Jun 8Jun 25

BioAtla, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.bioatla.com ↗

Price3.54

Change-6.60%

Gap+0.00%

Rel volume1.26×

Avg volume70.85K

Avg $ vol254.66K

SMA 203.59

SMA 504.11

SMA 2001.57

Price vs 50-13.93%

Price vs 200+125.84%

MA stackmixed

50/200 cross—

Supertrenddown · 4.37

RSI (14)47

MACD hist0.02

MACD crossbull · 4d

Stoch %K / %D38 / 47

ADX (14)19

+DI / −DI26 / 15

RSI divergence—

MACD divergence—

ATR %+11.05%

ADR %9.75%

52w high5.84

52w low0.1304

From 52w high-39.38%

Above 52w low+2614.72%

New 52w highNo

SqueezeOn · 10d

Bollinger width20.77%

%B0.43

Donchian pos38.19%

Donchian high4.22

Donchian low3.12

AVWAP (52w high)4.19

vs AVWAP high-15.52%

AVWAP (52w low)1.87

vs AVWAP low+89.34%

OBV trendFlat

Chaikin MF (20)-0.05

Today vs 20d1.26×

Avg vol (14d)67.19K

Avg vol (20d)70.85K

Avg $ vol (20d)254.66K

Market cap114.4M

RS 3m (vs SPY)+2446.82%

RS 6m (vs SPY)+395.32%

RS line new highNo

Trend template6/8

Technical rank68.5

1 week-0.28%

1 month-9.46%

3 months+2139.09%

6 months+343.61%

1 year+796.20%

YTD+562.67%

P/E-1.92

P/B-3.07

P/S381.32

P/FCF—

EPS-1.01

Div yield—

ROE159.77%

ROA—

Debt/Eq—

Current0.15

EV/EBITDA-1.91

Gross margin—

Net margin—

Rev growth0.00%

EPS growth14.57%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value112.44M

Revenue0

Net income-6.34M

Gross profit—

Free cash flow—

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out—

Employees41

ListedWed, Dec 16, 2020

Free float60.28M

Float %81.2%

Short interest147.63K

Days to cover3.5d

Short volume17.5%

Squeeze score22 / 100

Next earningsThu, Aug 6, 2026 (42d)

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeB

Conviction67 / 100

Pattern quality—

Tech rank68.5 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance5.00

Support3.19

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in BCAB

All disclosures →

No recent disclosed trades by Congress in BCAB. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in BCAB · 6 sells

Insider	Side	Shares	Value	Traded	Filed
Sievers Eric Chief Medical Officer · Common Stock · 2026-05-31	Tax	134	$527	2026-05-31	2026-06-05
SHORT JAY M PHD Chief Executive Officer · Common Stock · 2026-05-31	Tax	259	$1K	2026-05-31	2026-06-05
Vasquez Christian Chief Financial Officer · Common Stock · 2026-05-31	Tax	82	$322	2026-05-31	2026-06-05
SHORT JAY M PHD Chief Executive Officer · Common Stock · 2026-03-12	Tax	639	$107	2026-03-12	2026-06-05
SHORT JAY M PHD Chief Executive Officer · Common Stock · 2026-03-12	Other	—	—	2026-03-12	2026-06-05
Sievers Eric Chief Medical Officer · Common Stock · 2026-03-11	Tax	360	$61	2026-03-11	2026-06-05
Vasquez Christian Chief Financial Officer · Common Stock · 2026-03-11	Tax	175	$30	2026-03-11	2026-06-05

SEC filings

EDGAR filings in BCAB · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.